Magstim, a global leader in neuroscience and mental health treatment, has secured UKCA approval for its Horizon Inspire Transcranial Magnetic Stimulation (TMS) system. This landmark achievement will allow NHS physicians and private clinics in the UK to incorporate the advanced system into their patient care protocols for treating Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), and anxiety reduction*.
The Horizon Inspire system is a step forward in transcranial magnetic stimulation technology. It delivers a next-generation approach to treating mental health conditions with an emphasis on enhancing patient outcomes. “As pioneers in bringing clinical TMS to the NHS, our team is dedicated to advancing treatments for depression and anxiety,” said Professor Alex O’Neill Kerr, MBChB, Medical Director at Transforming Mind Solutions. “The new system enhances the reliable Magstim TMS technology, elevating it further to optimise patient outcomes.”
For more than three decades, Magstim has been supplying the NHS with TMS technology, and now the Horizon Inspire system is further solidifying its leadership in the field. “Transcranial magnetic stimulation is a proven and effective treatment with minimal side effects,” said Ronnie Stolec-Campo, CEO of Magstim. The Inspire system is crafted to allow both experienced TMS practitioners and newcomers to quickly administer treatments, offering a highly effective solution for enhancing patient results.
One of the most significant features of the Horizon Inspire system is its high-power air-cooling technology. The system provides an efficient way to deliver multiple treatments back-to-back, enhancing the overall treatment process for both patients and practitioners. The Inspire is cost-effective, easy to use, and portable, making it ideal for integration into both private clinics and NHS facilities. The system’s portability is an essential benefit, allowing it to be moved between rooms within a clinic with ease.
Magstim’s commitment to innovation is backed by substantial research and real-world clinical application. With over 20,000 peer-reviewed papers referencing its TMS technology, the company has a long-standing reputation for delivering effective and reliable solutions for treating mental health disorders. The Horizon Inspire system reflects the culmination of decades of TMS expertise, ensuring that patients receive the highest standard of care possible.
Additionally, the system comes equipped with intuitive preset clinical workflows, which help simplify the treatment process and ensure precise, reliable results. By eliminating pulse decay and ensuring accurate dosing, the Inspire system optimises treatment efficacy. The air-cooled coil not only reduces downtime but also eliminates the additional cost of cooling, which is a common issue in many TMS devices.
As the demand for non-invasive treatments for mental health issues like MDD and OCD continues to rise, TMS is increasingly seen as a viable alternative to traditional methods. The Horizon Inspire system is designed to meet this growing demand, offering healthcare providers a cutting-edge solution for delivering high-quality care. The system’s user-friendly design and advanced features make it a versatile tool for clinicians across the UK, helping them deliver effective treatments to patients suffering from these challenging conditions.
Magstim’s approach to TMS technology is unique in that the company does not charge pay-per-use fees for its equipment. This approach, combined with a dedicated support team, sets the company apart from others in the industry. The Horizon Inspire system is built with the intention of providing long-term value to healthcare providers, ensuring that TMS technology remains accessible and sustainable.
Magstim’s ongoing commitment to research and development means the company is well-equipped to continue leading the field of TMS technology. As more patients seek effective treatments for mental health conditions, the Horizon Inspire system is poised to play a pivotal role in improving the lives of those affected by depression, anxiety, and OCD.
